Rapport Therapeutics News

Rapport Therapeutics(RAPP.US) Director Buys US$1.08 Million in Common Stock

$Rapport Therapeutics(RAPP.US)$ Director HEALY JAMES purchased 44,032 shares of common stock on Jul 1, 2024 at an average price of $24.518 for a total value of $1.08 million.Source: Announcement What

Moomoo NewsJul 3 20:44 ET

Stifel Starts Rapport at Buy, Cites Lead Drug Candidate RAP-219

Seeking AlphaJul 2 14:45 ET

TD Cowen Initiates Rapport Therapeutics(RAPP.US) With Buy Rating

TD Cowen analyst Joseph Thome initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 34.2% and a total average return of

Moomoo NewsJul 2 06:31 ET · Ratings

Rapport Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 50.09% Stifel → $35 Initiates Coverage On → Buy

BenzingaJul 2 05:53 ET

Express News | Rapport Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

ReutersJul 2 05:48 ET

Stifel Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35

Stifel analyst Paul Matteis initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating, and sets the target price at $35.According to TipRanks data, the analyst has a success rate of 47.5

Moomoo NewsJul 2 05:31 ET · Ratings

Jefferies Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35

Jefferies analyst Andrew Tsai initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating, and sets the target price at $35.According to TipRanks data, the analyst has a success rate of 49

Moomoo NewsJul 2 05:31 ET · Ratings

Buy Rating for Rapport Therapeutics: Disruptive CNS Treatments and Promising Drug Efficacy

TipRanksJul 2 04:58 ET

Express News | Rapport Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $35

ReutersJul 2 00:35 ET

Express News | James I. Healy Reports 5.5% Stake in Rapport Therapeutics Inc as of June 10, 2024- SEC Filing

ReutersJun 14 16:02 ET

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering Thursday, Climbs Friday

Yahoo FinanceJun 14 12:08 ET

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational sma

GlobeNewswireJun 12 16:01 ET

Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply during Tuesday's session after the company announced pricing of $15 million underwritten public offering.Contango Ore shares dipped 18.4% to $20.3

BenzingaJun 11 13:54 ET

Rapport Therapeutics Starts Trading Above IPO Price

Seeking AlphaJun 7 12:04 ET

Express News | Rapport Therapeutics Shares Open at $18 in Nasdaq Debut Vs IPO Price of $17 per Share

ReutersJun 7 11:09 ET

Express News | Rapport Therapeutics IPO Shares Open For Trade At $18/Share; ; IPO Priced At $17 On 8M Shares

BenzingaJun 7 11:07 ET

Express News | Rapport Therapeutics IPO Price Indicating $18 On 196,335 Shares; IPO Priced At $17 On 8M Shares

BenzingaJun 7 10:33 ET

Express News | Rapport Therapeutics IPO Price Indicating $18 On 163K Shares

BenzingaJun 7 10:24 ET

Express News | Rapport Therapeutics IPO Price Indicating $18; 8M Share Offering Priced $17

BenzingaJun 7 10:01 ET

Trading Halt: Halt Status Updated at 9:50:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Trading Halt: Halt Status Updated at 9:50:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

BenzingaJun 7 09:50 ET